RSS

head and neck cancer

The European Patent Office has issued a new patent to biotechnology company, CEL-SCI, for its lead investigational immunotherapy, which is undergoing a Phase III clinical trial for head and neck cancer. Read more

Technology

An integrated oncology platform from Crown Bioscience has helped to advance the preclinical development of a HERA-GITRL immunotherapy from Apogenix for non-small cell lung cancer (NSCLC) and head and neck cancer. Read more

Technology

Nanobiotix is expanding and accelerating its clinical development activities, including its head and neck cancer programme and immune-oncology programme. Read more

News